Inhibikase Therapeutics, Inc.
Company Stats
- Market Cap
- $286.7M
- as of Sep 30, 2026
- Shares Outstanding
- 139.5M
- Free Float
- 68.2%
Income Statement
- Operating Income
- -$52.0M
- Net Income
- -$48.3M
- EBITDA
- -$51.9M
Cash Flow
- Free Cash Flow
- -$27.8M
- FCF Yield
- -9.7%
- Owner FCF Yield
- -15.0%
Balance Sheet
- Cash & Equivalents
- $178.8M
Returns & Capital
- SBC, 3Y Avg
- $8.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | — | -$27.8M | — |
| FY2024 | $0 | -$19.1M | — |
| FY2023 | $260,501 | -$18.1M | -6947.9% |
| FY2022 | $123,440 | -$17.6M | -14253.4% |
| FY2021 | $3.1M | -$14.3M | -461.1% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 13, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges